Atypical Teratoid/Rhabdoid Tumor Treatment Market
The atypical teratoid/rhabdoid tumor market growth is driven by rising molecular diagnosis and increased awareness of this aggressive pediatric CNS cancer, which is expanding the pool of identified patients.
Additionally, the launch of emerging therapies such as:
- PD-1 inhibitor (Nivolumab)
- Aurora A kinase inhibitor (Alisertib)
- C ClpP agonist and DRD2 antagonist (ONC206)
are further expected to propel the market.
No direct quote available in the given text.
Author summary: Growing clinical trials drive the market.
More News
- The desperate plea for the Dolphins to finally fire Mike McDaniel
- CNN's David Urban Says Dems Are Stoking Fear on Gay Marriage
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- Coloradans scramble for help as SNAP suspension looms and food banks ‘just don’t have enough’
- 'Love Island's' Huda Mustafa Apologizes After Laughing At Racist Slur Hurled Towards Olandria Carthen
- 'Days of Our Lives' Spoilers (Nov. 3-7): A Few Discoveries and an Adoption
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident
- Riley Green & Ella Langley Notch Second Top 10 Together on Country Airplay Chart